|  |  |  |  |
| --- | --- | --- | --- |
| **Analysis of participants lost to follow up** | **Mortality Data or Active** | **Lost to Follow up** | **p-value** |
| N | 1120 | 569 |  |
| Age at Symptom Onset (mean (SD)) | 62.00 (11.75) | 58.33 (13.20) | <0.001 |
| Definite ALS per El Escorial Criteria (%) | 338 (31.0) | 159 (28.7) | 0.371 |
| Upright Forced Vital Capacity at Screening (mean (SD)) | 76.01 (23.67) | 78.58 (24.96) | 0.102 |
| ALSFRS-R at Screening (mean (SD)) | 34.14 (9.35) | 34.44 (10.05) | 0.567 |
| Bulbar Onset (%) | 329 (29.9) | 125 (22.6) | 0.002 |
| History of Riluzole Usage (%) | 855 (76.3) | 421 (74.0) | 0.289 |
| Male (%) | 652 (59.3) | 330 (59.7) | 0.917 |
| Delay between symptom onset and ALS diagnosis (mean (SD)) | 17.12 (25.88) | 20.35 (28.34) | 0.02 |

Supplementary Table 3: Analysis of participants lost to follow up